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The chronicle backdrop of liver transplantation (LT) is an intricate story to 
reveal- it is an adventure of extraordinary achievement and catastrophic 
disappointments. Historically, controversies and LT seems to be 
synonymous.  
 
Despite the improvements in results, LT is still facing lots of challenges 
and controversies, whereby demand is high but the resources, primarily 
concerned to donor, are very limited. 
 
We have focused our perspective on LT for HCV-related cirrhosis and 
nutritional support for cachectic patients awaiting LT. 
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Liver transplantation (LT) is the gold standard 
and only cure for end-stage liver diseases. 
Demand of the organ, and low available donor 
pool have been marginally improved through 
innovations such as a living donor liver 
transplant, donation after circulatory death, 
split liver transplantation, auxiliary liver 
transplant, extended criteria for donors, 
extended criteria of LT for HCC, and ABO 
incompatible LT.1-3 Nonetheless, there are lots  
of controversies that are needed to be 
discussed among the transplant community, 
like selection of patients in need of LT, best 
use of new drugs, and new advancements, 
Figure 1. To discuss all the controversies in LT 
in detail will require separate extensive 
review, and is beyond the scope of this article 
with concise viewpoint we have put here for 
further debate. Here we have especially 
focused on LT for HCV-related cirrhosis and 
nutritional support for cachectic patients 




Figure 1. Recent controversies in liver transplantation1-5,7,9 
 
 
Note: ABOi: ABO incompatible; ABOc: ABO Compatible; ALF: Acute Liver Failure; ACLF: Acute on Chronic Liver Failure; 
ALD: Alcoholic Liver Disease; DBD: Donation after Brain Death; DCD: Donation after Circulatory Death; HCV: Hepatitis C 
Virus; LT: Liver Transplantation 
 
Liver transplant and hepatitis C virus (HCV)- 
Hepatitis C virus (HCV) infection is the leading 
cause of chronic liver disease and the third 
most common indications for LT in the United 
States.6 However, since the introduction of 
direct-acting antiviral (DAA) therapy the 
number of cases has declined in recent years. 
It is recommended that patients with HCV 
infection be treated ahead of LT as there is a 
high chance of HCV reinfection and graft 
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It is yet unsettled whether HCV-positive 
patients with Child grade C on the LT waiting 
list should be treated with DDA before 
transplant and practices differ in different 
regions and centers. 
 
At the time of organ shortage, donor pool can 
be increased by utilizing HCV-positive livers. In 
regions where HCV-positive livers are 
common, the accentuation will probably be 
not to treat HCV infected patients who are on 
the LT waiting list as HCV-positive livers can 
be available for such patients. However, in the 
regions where HCV-positive livers are not as 
common, the focus will be towards treating 
HCV-positive patients before the LT. Study 
shows large variations in the centers using 
HCV-positive liver, ranging between 0-40%.7 
Concurrently, a recent study shows 
transplantation of HCV-viremic livers into 
non-viremic recipients had acceptable short-
term outcomes and all the recipients achieved 
sustained virologic response (SVR) at 12 
weeks post-treatments with DAA-based 
regimens.8 The debate continue on utilization 
of HCV-positive livers and choice of treating 
the patients with HCV before the LT.  
 
Another factor is the Model for End-Stage 
Liver Disease (MELD) score at the time of the 
LT. In the centers where the MELD score of 
the patients is especially low, the emphasis 
will again be toward antiviral treatment prior 
to the LT. Such patients if treated with DDA 
can be virus-free with a SVR and then can be 
transplanted at generally lower MELD scores 
less than 25. However, in the centers where 
patients MELD scores are over 30, physicians 
are less likely to focus on treatment with DDA 
for those patients to render them virus-free 
and put them in the state called “MELD 
purgatory.” There is ongoing debate 
concerning why patients should not be 
treated when they are not too sick to undergo 
transplant, yet not in a good health to 
function satisfactorily. 
 
Last but not the least, patient's capacity to 
medication adherence and to complete the 
normal 12 weeks course of the DDA should be 
considered as patients with decompensated 
liver fails to complete their course due to 
repeated hospitalization. Therefore, the 
patients with decompensated liver are found 
to have a lower SVR rate contrasted with less 
sick patients. 
 
Despite the controversies, most physicians 
would presumably agree that patients with 
MELD scores of 20 or above are likely not a 
great contender for HCV treatment. 
Nevertheless, this issue largely varies among 
centers and geographical regions based upon 
physician’s understanding, the accessibility of 
HCV-positive organs, and the MELD score. 
 
Nutritional support for cachectic patients 
awaiting liver transplant - Frailty and 
sarcopenia have shown to pose an increased 
risk of morbidity and mortality for the patient 
on the waiting list and after LT. Frailty is 
impartially evaluated through performance 
based, for example, grasp strength and gait 
speed, chair stands, and balance, though 
sarcopenia is formally evaluated by 
estimation of the psoas muscle zone on cross-
sectional imaging or using whole-body 
bioelectrical impedance. There are more 
ongoing studies to characterize these patients 
and assess them for potential treatments 
more readily. 
 
Malnourished and sarcopenic patients waiting 
for LT have longer ICU/hospital stay, higher 
incidence of infections and a lower 1-year 
survival.9 Generally, 20%-60% of patients with 
cirrhosis develop malnutrition and 
sarcopenia.9 Preoperative immunonutrition 
like omega-3 fatty acids, arginine and 
nucleotides fortified with oral nutritional 
supplements are recommended for the 
patients waiting for LT.9 A meta-analysis 
investigating various peri-operative 
immunonutrition like glutamine or omega-3 
fatty acids, arginine, and ribonucleic acids 
found significant reduction in infectious 
complications and improvement in liver 
function post LT; however, there was no 
significant difference in overall survival.10 
Likewise, Kaido et. al., reported fewer 
postoperative infectious complications after 





Dipesh K Yadav: Recent controversies in liver transplantation 
Journal of Patan Academy of Health Sciences. 2020Aug;7(2):98-102. 
 
immunonutrition. Surprisingly, preoperative 
branched chain amino acid only showed 
better survival outcome for patients with 
sarcopenic on the waiting list; however, it 
failed to improve survival in non-sarcopenic 
patients.11 In contrast, the randomized trial 
didn’t find any significant benefits of 
perioperative immunonutrition in patients 
undergoing LT in terms of preoperative 
nutritional status or postoperative outcome 
compared to standard oral nutritional 
intervention.12  
 
Together with recent understanding of 
sarcopenia, the issue of overweight and 
corpulence in cirrhotic patients warrants 
further investigation. Some advantages of 
physical activity are observed in cirrhotic 
patients and requires further studies.9  
 
To conclude, liver glycogen is exhausted in 
patients with cirrhosis. Thus, it is prudent to 
minimize the interval without nutrient 
consumption to dodge gluconeogenesis from 
muscle protein in a previously protein 
depleted patients. The interest to characterize 
and treat frailty and sarcopenia in the patient 
waiting for LT is rapidly increasing. There is 
need for large, well-powered long-term 
observational studies of homogeneous groups 
of patients that can provide the ideal 
treatment for anticipation or reversal of frailty 
and sarcopenia. 
 
Future perspectives- In general, LT is an 
exhilarating field of research. Current 
knowledge in the field is mostly based on 
retrospective, single-center studies, and we 
should aim to for larger, multi-center 
prospective studies. LT leaves a wealth of 
opportunities for doctors to learn not only 
about the liver, but also about immunology, 
pharmacology, oncology, psychology, 
infectious diseases, and cardiovascular 
diseases to name a few. 
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